Two Phase 3 CLL trials—BRUIN CLL-313 and BRUIN CLL-314—were published after December 2025 results, placing chronic lymphocytic leukemia at a clinical and regulatory crossroads. The report highlights pirtobrutinib, a noncovalent BTK inhibitor, and notes that experts urge caution over treatment order despite the strong signals. The emphasis on sequencing reflects how therapy ordering can change response rates, resistance patterns, and subsequent line options. In practice, this can influence guideline adoption and center prescribing behaviors once regulatory reviews finalize. For biotech and partners, the update matters because it shapes the competitive landscape for next-generation BTK inhibitor and combination strategies targeting the same patient segments.